<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="1 Rilpivirine Inhibits ZIKV by Blocking Viral RdRp (A) Proposed" exact="rilpivirine" post="binding site on ZIKV RdRp. ZIKV NS5 (PDB: 5TMH)15"/>
 <result pre="PyMOL. (B) In vivo efficacy. Treatment of ZIKV-infected mice with" exact="rilpivirine" post="suppressed viral replication and prevented animal death. First, Sariyer"/>
 <result pre="ZIKV infection of astrocytes as a screening assay, they identified" exact="rilpivirine" post="as a ZIKV inhibitor from eight FDA-approved HIV nucleoside"/>
 <result pre="killing of non-tumor cells. It remains to be tested if" exact="rilpivirine" post="also inhibits closely related flaviviruses, such as dengue, yellow"/>
 <result pre="viruses. Nevertheless, the authors have established the antiviral activity of" exact="rilpivirine" post="against ZIKV in cell culture. Second, Sariyer et al.2"/>
 <result pre="et al.2 provided five lines of evidence to support that" exact="rilpivirine" post="targets ZIKV RdRp (Figure 1A). (1) Computational docking suggests"/>
 <result pre="targets ZIKV RdRp (Figure 1A). (1) Computational docking suggests that" exact="rilpivirine" post="may bind to the palm site of RdRp protein."/>
 <result pre="site of RdRp protein. (2) Differential scanning fluorimetry showed that" exact="rilpivirine" post="binds to recombinant RdRp with a KD of 100"/>
 <result pre="cells, but not the 14-amino acid mutant protein, competed for" exact="rilpivirine" post="binding and thus alleviated compound-mediated antiviral activity. Although these"/>
 <result pre="improved potency. (2) The selection of ZIKV variants resistant to" exact="rilpivirine" post="will identify mutations that are likely mapped to the"/>
 <result pre="Third, Sariyer et al.2 demonstrated the in vivo efficacy of" exact="rilpivirine" post="in a ZIKV interferon α/β receptor (IFNAR)−/− mouse (type"/>
 <result pre="knockout) model (Figure 1B). Treatment of ZIKV-infected IFNAR−/− mice with" exact="rilpivirine" post="reduced organ viral burden and weight loss, improved clinical"/>
 <result pre="caused significant inflammation and abundant apoptotic/necrotic cell damage. Treatment with" exact="rilpivirine" post="reduced the levels of viral RNA in the brain"/>
 <result pre="but it did not eliminate inflammation. These results indicate that" exact="rilpivirine" post="suppressed viral replication and disease development. However, it was"/>
 <result pre="better in vivo efficacy. Nevertheless, the in vivo potency of" exact="rilpivirine" post="seems better than sofosbuvir, a hepatitis C virus (HCV)"/>
 <result pre="(HCV) nucleoside drug that was reported with anti-ZIKV activity.9 Specifically," exact="rilpivirine" post="completely protected ZIKV-infected mice from death, whereas sofosbuvir and"/>
 <result pre="activity.9 Specifically, rilpivirine completely protected ZIKV-infected mice from death, whereas" exact="sofosbuvir" post="and other nucleoside inhibitors only conferred partial protection.10 The"/>
 <result pre="readily advanced to clinical trials for the new indication.11 As" exact="rilpivirine" post="inhibits HIV-1 and ZIKV with EC50 in the single-digit"/>
 <result pre="to ensure clinical efficacy in patients. To achieve this goal," exact="rilpivirine" post="analogs previously synthesized during lead optimization could be tested"/>
 <result pre="with better potency for ZIKV may be identified from the" exact="rilpivirine" post="analogs. Meanwhile, efforts could be made to solve the"/>
</results>
